Interview by Newsweek, Time to Talk

An interview with Dr. Steve J.P. Hsu, President of Genovior Biotech.

Given your professional background with more than 25 years of experience in the pharmaceutical and biotech industry, what made you decide to found Genovior Biotech?

I started my career in 1989, when I graduated from MIT and started working with Merck in the United States. Thereafter, I returned to Taiwan and worked for ScinoPharm, which was the largest API company in Taiwan at that time. In 2004, I founded Savior Lifetec, where I created new technology not only for manufacturing sterile drugs, but also for injectables.

I founded Genovior three years ago, and today we have about 150 employees. We are currently producing small molecular and large molecular pharmaceuticals, from API all the way to injectables. We have oncology, peptide, and microbial process-related protein drugs. We also provide CDMO services, which were our core objective when we first began, as well as products related to biosimilars.